Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Research explores ... outcomes research also   to   be presented ... SHPG ), the global specialty biopharmaceutical company, announces that ... at the American Psychiatric Association (APA) 166th Annual Meeting ... The data being presented represent Shire,s ongoing commitment to ...
(Date:5/17/2013)... /PRNewswire-iReach/ -- The escalation of new biological drugs, ... emphasis on alternate delivery technologies. Alternate delivery technologies ... factors are converging to create both risk ... device partners . These include new classes of ... toward self-administration for chronic diseases, shifting patient demographics ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
(Date:5/18/2013)... -- Children who swallow high-powered magnets often need surgery ... to a new study. The researchers, from the ... that more than 79 percent of children who swallowed ... endoscopic procedure, in which a tube containing a camera ... of these cases can be treated through observation or ...
(Date:5/18/2013)... published an original art book for iPad with tango as ... who share their creations based on the traditional music genre ... iPad . , This work gathers more than 150 ... signature idiosyncrasy and passion of tango. Such book is ... it includes a free trailer of the book for readers ...
(Date:5/18/2013)... 2013) There are significant cost and risk ... diagnose or treat gastrointestinal problems, according to research ... A study by New York Presbyterian Hospital and ... may substantially reduce the cost and risk of ... believed to affect nearly 25 percent of adults, ...
(Date:5/18/2013)... May 18, 2013 In a May ... Preventive Double Mastectomy After Discovering Cancer Gene,” Fox News ... procedure upon learning that she carried a gene that ... breast cancer and a 50 percent risk of ovarian ... up on May 16, 2013 with a blog post ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New Art Book for iPad: Tango Art 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4
... A resource for medical educators interested improving their teaching ... advancing their careers in medical education is now available ... Teaching Medicine series is the first of its kind," ... summarizes the important literature of medical education and shares ...
... Health Care is undertaking an electronic medical record integration ... project is a multi-year, multi-entity corporate initiative to implement ... variability in processes and workflows across the system. Currently ... the next four years, the way UMass Memorial collects, ...
... beforehand upped students, grades, study found , THURSDAY, April 1 (HealthDay ... a little more likely? , Perhaps, according to a study ... test depressed college students, grades. , Test-takers who saw the letter ... to do with a grade, scored significantly worse than those who ...
... for women at increased risk , THURSDAY, April 1 (HealthDay News) ... boosts the risk that a woman will develop breast cancer. But ... of cancer in mice with that gene by deactivating another gene. ... 85 percent greater lifetime risk for developing breast cancer than other ...
... hyperthyroidism should have it treated to reduce their ... -- Young adults who have an overactive thyroid face ... the condition, Taiwanese researchers report. , "This is a ... treatment to prevent these complications," Dr. Majaz Moonis, ...
... ... Fekrat of AfghanLord about the situation of opium and heroin addicts within Afghanistan. ... 1.5 million addicts within the country and the capital city of Kabul. ... day. This health crisis is ruining families who do not know the ...
Cached Medicine News:Health News:UMass Memorial health care develops fully integrated EMR 2Health News:Seeing Letter 'F' May Lower Test Scores 2Health News:Overactive Thyroid Linked to Stroke in Young Adults 2Health News:Interview: Heroin Addicts in Afghanistan: An Inside Look 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: